169 related articles for article (PubMed ID: 22008148)
1. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
Onoue S; Sato H; Ogawa K; Kojo Y; Aoki Y; Kawabata Y; Wada K; Mizumoto T; Yamada S
Eur J Pharm Biopharm; 2012 Jan; 80(1):54-60. PubMed ID: 22008148
[TBL] [Abstract][Full Text] [Related]
2. Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy.
Sato H; Ogawa K; Kojo Y; Kawabata Y; Mizumoto T; Yamada S; Onoue S
Int J Pharm; 2013 May; 448(1):282-9. PubMed ID: 23528280
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.
Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S
J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169
[TBL] [Abstract][Full Text] [Related]
4. Self-micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments.
Suzuki H; Ueno K; Mizumoto T; Seto Y; Sato H; Onoue S
Eur J Pharm Sci; 2017 Jan; 96():107-114. PubMed ID: 27634579
[TBL] [Abstract][Full Text] [Related]
5. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.
Onoue S; Aoki Y; Kawabata Y; Matsui T; Yamamoto K; Sato H; Yamauchi Y; Yamada S
J Pharm Sci; 2011 Feb; 100(2):622-33. PubMed ID: 20653048
[TBL] [Abstract][Full Text] [Related]
6. Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.
Seto Y; Suzuki G; Leung SS; Chan HK; Onoue S
Pharm Res; 2016 Jun; 33(6):1447-55. PubMed ID: 26975360
[TBL] [Abstract][Full Text] [Related]
7. [Strategic formulation study on dry powder inhalation system based on modulated molecular properties and controlled pharmacokinetics].
Onoue S
Yakugaku Zasshi; 2013; 133(1):93-8. PubMed ID: 23292025
[TBL] [Abstract][Full Text] [Related]
8. Strategic application of self-micellizing solid dispersion technology to respirable powder formulation of tranilast for improved therapeutic potential.
Suzuki H; Kojo Y; Yakushiji K; Yuminoki K; Hashimoto N; Onoue S
Int J Pharm; 2016 Feb; 499(1-2):255-262. PubMed ID: 26748364
[TBL] [Abstract][Full Text] [Related]
9. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability study on cyclosporine A loaded dry-emulsion formulation with enhanced solubility.
Sato H; Ogawa K; Kojo Y; Suzuki H; Mizumoto T; Onoue S
Chem Pharm Bull (Tokyo); 2015; 63(1):54-8. PubMed ID: 25743195
[TBL] [Abstract][Full Text] [Related]
11. Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization.
Suzuki H; Moritani T; Morinaga T; Seto Y; Sato H; Onoue S
Int J Pharm; 2017 Mar; 519(1-2):213-219. PubMed ID: 28093327
[TBL] [Abstract][Full Text] [Related]
12. New nano-matrix oral formulation of nanoprecipitated cyclosporine A prepared with multi-inlet vortex mixer.
Suzuki H; Hamao S; Seto Y; Sato H; Wong J; Prud'homme RK; Chan HK; Onoue S
Int J Pharm; 2017 Jan; 516(1-2):116-119. PubMed ID: 27845213
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.
Sato H; Suzuki H; Yakushiji K; Wong J; Seto Y; Prud'homme RK; Chan HK; Onoue S
Pharm Res; 2016 Sep; 33(9):2107-16. PubMed ID: 27225495
[TBL] [Abstract][Full Text] [Related]
14. Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.
Onoue S; Seto Y; Kato M; Aoki Y; Kojo Y; Yamada S
Pharm Res; 2013 Jun; 30(6):1586-96. PubMed ID: 23430486
[TBL] [Abstract][Full Text] [Related]
15. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.
Onoue S; Matsui T; Kuriyama K; Ogawa K; Kojo Y; Mizumoto T; Karaki S; Kuwahara A; Yamada S
Peptides; 2012 Jun; 35(2):182-9. PubMed ID: 22484228
[TBL] [Abstract][Full Text] [Related]
16. Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
Onoue S; Sato H; Ogawa K; Kawabata Y; Mizumoto T; Yuminoki K; Hashimoto N; Yamada S
Int J Pharm; 2010 Oct; 399(1-2):94-101. PubMed ID: 20705124
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A.
Matilainen L; Järvinen K; Toropainen T; Näsi E; Auriola S; Järvinen T; Jarho P
Int J Pharm; 2006 Aug; 318(1-2):41-8. PubMed ID: 16624508
[TBL] [Abstract][Full Text] [Related]
18. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
[TBL] [Abstract][Full Text] [Related]
19. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
[TBL] [Abstract][Full Text] [Related]
20. Inhaled sildenafil nanocomposites: lung accumulation and pulmonary pharmacokinetics
Ghasemian E; Vatanara A; Rouini MR; Rouholamini Najafabadi A; Gilani K; Lavasani H; Mohajel N
Pharm Dev Technol; 2016 Dec; 21(8):961-971. PubMed ID: 26428267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
